COMMUNIQUÉS West-GlobeNewswire

Kyowa Kirin reprend le contrôle du programme de développement et de commercialisation du rocatinlimab, manifestant ainsi son profond engagement visant à répondre aux besoins médicaux non satisfaits dans le domaine de la dermatite atopique
31/01/2026
Kyowa Kirin réaffirme sa volonté de développer le rocatinlimab comme un traitement innovant capable d’améliorer significativement la vie des patients, tout en offrant un fort potentiel commercial. L’approche novatrice [...]
New employee representative on the Board of Directors of Novo Nordisk A/S
31/01/2026
Bagsværd, Denmark, 31 January 2026 – Thomas Rantzau, employee representative on the Board of Directors since 2018, has decided to pursue new opportunities outside Novo Nordisk A/S after 22 years of employment. Therefore [...]
Embers to Empowerment: The Womb Room Reopens in Govans, Expanding Community-Centered Perinatal Care After Hampden Fire
31/01/2026
Baltimore, Maryland, Jan. 31, 2026 (GLOBE NEWSWIRE) -- After sustaining water damage during the massive November 2025 fire at Keswick Castle in Hampden, The Womb Room , a Baltimore-based perinatal wellness center, has [...]
Olema Oncology Announces Departure of Chief Operating and Financial Officer
30/01/2026
SAN FRANCISCO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]
NurExone Appoints Eyal Gabbai to Board, Adding Large-Scale Healthcare System and Capital Markets Expertise
30/01/2026
Chairman of Meuhedet, Israel’s third-largest health fund TORONTO and HAIFA, Israel, Jan. 30, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”) today [...]
Crescent Biopharma Announces Grants of Inducement Awards
30/01/2026
WALTHAM, Mass., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies [...]
Enzon Announces Commencement of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock in Connection With Viskase Merger
30/01/2026
CRANFORD, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“Enzon” or the “Company”), today announced that it has commenced an exchange offer (the “Offer”) involving its Series C Non- [...]
Achieve Life Sciences Announced Granting of New Hire Inducement Awards
30/01/2026
SEATTLE and VANCOUVER, British Columbia, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and [...]
Oxford Healthspan to Introduce New Primeadine® GF Powder Through a ‘Longevity Shot’ Experience During Grammy Week in Los Angeles
31/01/2026
Science-Backed Spermidine Ritual Brings Cellular Renewal to a High-Performance Cultural Moment LOS ANGELES, Jan. 30, 2026 (GLOBE NEWSWIRE) -- As part of Grammy Week in Los Angeles, Oxford Healthspan will offer a preview [...]
Park Dental Partners Announces Dates for Fourth Quarter and Full Year 2025 Earnings Release and Conference Call
30/01/2026
MINNEAPOLIS, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Park Dental Partners, Inc. (NASDAQ: PARK), a leading dental resource organization, today announced that it will report its financial results for the fourth quarter and full [...]
Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders
30/01/2026
WARREN, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ) today announced that its Board of Directors has expressed its intention to evaluate the potential [...]
OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting
30/01/2026
LONDON and NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain ( [...]
CrazyBulk: SARM Alternatives for Bulking, Strength and Performance or Just Hype?
30/01/2026
New York City, NY, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Visit Official CrazyBulk Website Here TL;DR Summary: A lot of athletes, whether they are professionals or just training for personal goals, eventually hit a point [...]
Elevar Therapeutics Announces FDA Acceptance of New Drug Application Resubmission for Rivoceranib in Combination with Camrelizumab as a First-line Systemic Treatment for Unresectable Hepatocellular Carcinoma
30/01/2026
FDA sets PDUFA target action date of July 23, 2026 FORT LEE, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical [...]
Dr. Linette Williamson Expands Integrative Medicine Services in Encinitas With Physician-Supervised Ozone Sauna Therapy
30/01/2026
Encinitas, CA, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Dr. Linette Williamson, MD, a physician with extensive experience in emergency medicine and integrative functional care, is expanding the therapeutic services offered at [...]
IO Biotech Provides Corporate Update
30/01/2026
Raymond James engaged as financial advisor Reduction in force implemented NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune- [...]
ALX Oncology Announces Pricing of Underwritten Offering
30/01/2026
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat [...]
Ultragenyx Resubmits Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) to U.S. FDA
30/01/2026
Company expects up to six-month review period per FDA guidelines New longer-term clinical data demonstrating durable positive brain biochemical and clinical effect for as long as 8.5 years to be presented at [...]
New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer
30/01/2026
- Exploratory analysis from Phase 1b/2 breast cancer trial reinforces CD47 as a predictive biomarker for response, as previously observed in the ASPEN-06 trial in HER2-positive gastric cancer – - Full data set submitted [...]

Pages